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Introduction {#sec005}
============

Reference intervals (RIs) are an integral part of laboratory reports as they assist clinicians in interpretation of results. RIs should be population specific to ensure appropriate interpretation. Unfortunately, many clinical laboratories in sub-Saharan Africa (SSA) adopt RIs provided by manufacturers of laboratory reagents/equipment without verifying them as recommended by the Clinical Laboratory Standards Institute (CLSI) \[[@pone.0235234.ref001]\]. This could result in inaccurate interpretation of quantitative laboratory results leading to medical errors. Saathoff *et al* carried out a study in the Mbeya region, south-western Tanzania and found marked differences in RIs from the United States (US), Tanzania and other SSA countries. Overall, only 80.9% of reference values (RVs) for clinical chemistry tests from healthy individuals in Tanzania would have been classified as normal as per the US RIs published by Kratz *et al* \[[@pone.0235234.ref002]\].

The International Federation of Clinical Chemistry (IFCC) under its Committee on Reference Intervals and Decision Limits (C-RIDL) has been carrying out a global RI study using a protocol that harmonizes the pre-analytical, analytical and post-analytical study processes to ensure ease of comparison of derived RIs across different regions, countries and ethnicities \[[@pone.0235234.ref003]\].

An interim report of the global RI study comprising data from 12 countries identified between ethnic group differences in both males and females for serum total protein (TP), albumin (Alb), total bilirubin (TBil), high density lipoprotein cholesterol (HDL-C), magnesium (Mg), C-reactive protein (CRP), IgG, complement 3 (C3), vitamin B12, and folate. Females were found to generally have more pronounced age-related changes in RVs. Ethnic differences in BMI-related changes was also demonstrated. The only African country whose data were included in the interim report was South Africa where comparisons between black South Africans and Caucasian / mixed race showed much higher levels of CRP in the black South Africans \[[@pone.0235234.ref004]\].

The Kenyan study was undertaken to explore sources of variation of RVs, to derive country specific RIs and to standardize the RIs by use of a value-assigned panel of sera \[[@pone.0235234.ref004]\] intended for nationwide use and international comparison.

Materials and methods {#sec006}
=====================

The methodology used in recruiting participants for the study, sample collection, handling and analysis has previously been published \[[@pone.0235234.ref005]\]. The study was approved by the Aga Khan University Hospital Nairobi (2014/REC-46) and Stellenbosch University (S16/10/219) Health Research Ethics Committees. The study was conducted in conformity with the Declaration of Helsinki.

Study population {#sec007}
----------------

Recruitment of study participants in Kenya was carried out between January and October 2015 in several counties. Majority were urban dwellers from the capital city Nairobi, Kiambu county in central Kenya, Kisii County in western Kenya, and Nakuru County based in the Great Rift Valley.

Inclusion and exclusion criteria {#sec008}
--------------------------------

Inclusion of participants was limited to healthy adults aged 18--65 years stratified into 4 age groups: 18--29, 30--39, 40--49 and 50--65 years. Exclusion criteria included individuals with a body mass index (BMI) \>35 kg/m^2^, consumption of ethanol ≥70 g per day, smoking \>20 cigarettes per day, taking regular medication for a chronic disease (diabetes mellitus, hypertension, hyperlipidemia, allergic disorders, depression), recent (\< 15 days) recovery from acute illness, injury or surgery requiring hospitalization, carrier of HBV, HCV or HIV, pregnant or within 1 year after delivery. Written informed consent was obtained after written/verbal explanation of the study. Those with any chronic disease were excluded except for individuals aged 50--65 years who had well controlled hypertension taking up to 2 drugs. A single measurement of blood pressure, abdominal circumference and BMI was done after filling the study questionnaire.

Blood collection and handling {#sec009}
-----------------------------

Blood samples were collected by trained phlebotomists into a serum separator tube for all analytes tested in serum, lithium heparin tube for troponin I, sodium fluoride tube for plasma glucose. Serum and plasma samples requiring centrifugation were spun 2--4 hours after collection and stored at −80°C at the Aga Khan University Hospital, Nairobi (AKUHN). Centrifugation was done at 2000g, for 10 mins in a non-refrigerated centrifuge (Beckman coulter, Allegra X-30, Brea, California, US) These were subsequently shipped frozen to the PathCare reference laboratory in Cape Town, South Africa for analysis. We also drew 2mL of whole blood for testing hematology parameters using Beckman-Coulter ACT5-DIFF-CP analyser (Brea, California, US), tested in PathCare Nairobi. The test results were primarily used for establishing RIs for hematology parameters \[[@pone.0235234.ref005]\], but they were referred to in this study for secondary exclusion of individuals with latent anemia or inflammation.

Measurements {#sec010}
------------

The analysis of all serum specimens was performed in batches on the Beckman Coulter AU 5800 (Brea, California, US) for chemistry assays and DXI (Brea, California, US) for immunoassays as summarized in [Table 1](#pone.0235234.t001){ref-type="table"}.

10.1371/journal.pone.0235234.t001

###### Summary of tests, equipment, assay methods and analytical performance.

![](pone.0235234.t001){#pone.0235234.t001g}

  Analyte                                Abbreviation   Method                                         Units    Between Run CV
  -------------------------------------- -------------- ---------------------------------------------- -------- ----------------
  Sodium                                 Na             Ion selective electrode / diluted (indirect)   mmol/L   1.3
  Potassium                              K              Ion selective electrode / diluted (indirect)   mmol/L   3.8
  Chloride                               Cl             Ion selective electrode / diluted (indirect)   mmol/L   1.4
  Urea                                   Urea           Urease                                         mmol/L   2.4
  Creatinine                             Cre            Modified kinetic Jaffè                         μmol/L   1.6
  Total Protein                          TP             Biuret                                         g/L      4.6
  Albumin                                Alb            Bromocresol Green dye binding                  g/L      2.8
  Total Bilirubin                        TBil           Diazonium salt                                 μmol/L   7.7
  Gamma-glutamyl transferase             GGT            Gamma-glutamyl-3-carboxy-4-nitroanilide        IU/L     3.3
  Alkaline phosphatase                   ALP            P-nitro-phenylphosphate hydrolysis             IU/L     4.0
  Lactate dehydrogenase                  LDH            Lactate to Pyruvate                            IU/L     3.2
  Calcium                                Ca             Arsenazo III dye                               mmol/L   1.4
  Magnesium                              Mg             Xylidyl blue                                   mmol/L   1.9
  Phosphate                              IP             Molybdate hydolysis                            mmol/L   1.8
  Lipase                                 Lip            1, 2-Diglyceride hydrolysis                    U/L      8.0
  Total cholesterol                      TC             Cholesterol oxidase                            mmol/L   1.2
  Triglycerides                          TG             Glycerol phosphate oxidase                     mmol/L   4.1
  High density lipoprotein cholesterol   HDL-C          Two phase selective accelerator detergent      mmol/L   2.0
  Low density lipoprotein cholesterol    LDL-C          Two phase selective accelerator detergent      mmol/L   1.6
  Uric acid                              UA             Modified Trinder reaction with Uricase         mmol/L   1.2
  High sensitive c reactive protein      CRP            Turbidimetry                                   mg/L     1.8
  Amylase                                AMY            2-chloro-4-nitrophenyl-α-D-maltotrioside       U/L      8.1
  Immunoglobulin A                       IgA            Turbidimetry                                   g/L      1.3
  Immunoglobulin G                       IgG            Turbidimetry                                   g/L      1.1
  Immunoglobulin M                       IgM            Turbidimetry                                   g/L      7.0
  Alanine aminotransferase               ALT            NADH (without P-5′-P)                          U/L      28.1
  Aspartate aminotransferase             AST            NADH (without P-5′-P)                          U/L      5.6
  Creatinine kinase                      CK             Creatine phosphate dephosphorilysation         U/L      6.5
  Iron                                   Fe             2, 4, 6-Tri-(2-pyridyl)-5-triazine chromogen   μmol/L   4.2
  Transferrin                            Tf             Turbidimetry                                   g/L      2.6
  Anti-thyroglobulin                     TgAb           Two-site immune---enzymatic immunoassay        IU/ml    4.8
  Anti-thyroid peroxidase                TPOAb          Two-site immune---enzymatic immunoassay        IU/ml    28.8
  Thyroid stimulating hormone            TSH            Two-site immune---enzymatic immunoassay        mIU/L    13.0
  Free thyroxine                         FT4            Two-site immune---enzymatic immunoassay        pmol/L   8.1
  Free tri-iodothyronine                 FT3            Two-site immune---enzymatic immunoassay        pmol/L   4.8
  Ferritin                               Fer            Turbidimetry                                   μg/L     8.2
  Prostate specific antigen              PSA            Two-site immune---enzymatic immunoassay        μg/L     2.3

As calculated parameters, globulin (Glb) was computed as TP---Alb; non-HDL-C as TC---HDL-C; HDL-C ratio (HDLrat) as TC/HDL-C.

Quality control {#sec011}
---------------

The PathCare reference laboratory is accredited by the South African National Accreditation System. For purposes of the global RI study, all participating laboratories received a panel of sera produced by the C-RIDL in 2014 that had assigned values \[[@pone.0235234.ref004]\]. This panel was measured by participating laboratories to enable recalibration of RVs using linear regression analysis. It also allowed for alignment of RVs across different countries by all-pairwise comparison of test results.

Statistical analysis {#sec012}
--------------------

In order to assess sex, age and BMI as sources of variation, we adopted the standard deviation ratio (SDR), which represents a ratio of between-subgroup SD (variation of the subgroup means from grand mean) to between-individual SD (approximately 0.25 the width of RI). For calculating SDRs, we first performed 2-level nested ANOVA to compute between-sex SD and between-age SD after partitioning age at 30, 40, and 50 years. With the results, the SDR for between-sex SD (SDRsex) and between-age SD (SDRage) were calculated as a ratio to the residual SD that corresponds to roughly between-individual SD or SD comprizing RI (SD~RI~. Since between-age variation changes by sex, we also computed SDRage for each sex by one way ANOVA. We considered SDR≥0.40 as a primary criterion for judging the need for partitioning RVs by sex and/or age \[[@pone.0235234.ref005]\].

However, SDR represents between-subgroup difference at the center of the RV distribution, which may not reflect the difference (bias) at LL or UL (ΔLL or ΔUL). Therefore, we also evaluated ΔLL or ΔUL as its ratio to SD comprising RI (SD~RI~) \[= \|UL−LL\|/3.92\] and expressed it as bias ratio (BR) at LL or UL (BR~LL~ or BR~UL~). For example, the formula for determining BR for sex was: $$\text{BR}_{\text{LL}} = \frac{\left| {\text{LL}_{M} - \text{LL}_{F}} \right|}{\left( {\text{UL}_{MF} - LL_{MF}} \right)/3.92},{\quad\text{BR}}_{\text{UL}} = \frac{\left| {\text{UL}_{M} - \text{UL}_{F}} \right|}{\left( {\text{UL}_{MF} - LL_{MF}} \right)/3.92}$$ where subscripts of MF, M, and F attached to LL or UL indicate the RI without partition by sex (for male+female) and the RIs after partition by male and female, respectively \[[@pone.0235234.ref006]\]. The same calculation was done for judging the need for age-specific RIs by setting LL, UL with/without partitioning by age. The distinction of the concepts between SDR and BR is illustrated in [Fig 1](#pone.0235234.g001){ref-type="fig"}.

![SD ratio (SDR) vs. bias ratio (BR) as a measure of between-subgroup differences.\
**SDR** represents between-subgroup differences at the center of distributions, while **BR** represents between-subgroup differences at the periphery (LL or UL) of the distributions. The numerator of SDR is between-subgroup SD (or SDsex, if sub-grouped by sex), while that of BR is a difference of LLs or ULs.](pone.0235234.g001){#pone.0235234.g001}

In setting the threshold for the bias ratios, we followed the convention of allowable limits of bias in measurements: $\sqrt{{SD}_{I}^{2} + {SD}_{G}^{2}} \leq 0.375$, where SD~I~ and SD~G~ represent within-individual and between-individual SD \[[@pone.0235234.ref007]\]. Since SD~RI~ or the denominator of BR is composed of both SD~I~ and SD~G~ and equal to $\sqrt{{SD}_{I}^{2} + {SD}_{G}^{2}}$, we set 0.375 as a threshold for BR. This scheme was adopted in recent papers \[[@pone.0235234.ref008],[@pone.0235234.ref009]\]. On the other hand, both SDR and BR depend on their common denominator, SD~RI~. For example, when the RI is narrow, both ratios can be inflated. Conversely, when the RI is wide, both ratios are suppressed. In order to cope with such situations, we set a pragmatic third criterion that between-subgroup bias at LL or UL (ΔLL or ΔUL) should be equal to or more than 3 times the "reporting unit (RU)" to allow partitioning of RVs. RU represents a unit of value for reporting test results. If the number of digits below the decimal point in reporting test results is 2, 1, or 0, RU is 0.01, 0.1, or 1, respectively. The flow of logic in deciding the need for partitioning by sex or age is shown in [Fig 2](#pone.0235234.g002){ref-type="fig"}.

![Scheme for partitioning RVs by sex and age.\
We adopted this flow-chart in judging the needs for partitioning RVs by sex and age. We defined between-sex (or -age) subgroup bias in reference to the three points: 1) SDR\>0.4 that represents the between-subgroup bias at the center of RV distribution, 2) BR\>0.375 that represents the between-subgroup bias at the limits (LL or UL) of RV distribution, and 3) the actual difference (bias) ≤ three reporting unit (RP). There were eight possible choices for the partitioning.](pone.0235234.g002){#pone.0235234.g002}

RIs were determined using both parametric and non-parametric methods before and after applying the latent abnormal values exclusion (LAVE) method \[[@pone.0235234.ref010],[@pone.0235234.ref011]\]. For the non-parametric method, the RVs coinciding with the 2.5^th^ and 97.5^th^ percentiles after sorting the data in ascending order were used as the lower and upper limits (LL, UL) of the RI. For the parametric method, the RVs were transformed into a Gaussian form by the Box-Cox power transformation formula, and then mean±1.96 SD was computed as the central 95% limits (LL−UL) under the transformed scale, which were then reverse transformed to get the LL and UL in the original scale \[[@pone.0235234.ref011]\].

As a measure for secondary exclusion of abnormal values, we tried to apply LAVE in deriving the RI both by parametric and nonparametric methods \[[@pone.0235234.ref011]\]. For LAVE, we primarily used the following set of reference tests: Alb, Glb, UA, Glu, non-HDL, TG, ALT, AST, LDH, CK, GGT, and CRP, which were meant for excluding individuals with inappropriate values in the nutritional, inflammatory, or muscular damage markers. As an exception, for iron related analytes (Fe, Ferr, Tf, and TfSat), we set hemoglobin (Hb), hematocrit (Hct), and mid-corpuscular volume (MCV) in addition to the four iron markers as the reference tests. For proteins (TP, Alb, Glb, IgG/A/M, CRP), we set all the seven tests plus white blood cell and platelet counts as the reference tests.

On the other hand, for determination of RIs for the thyroid panel, the LAVE procedure was not applied because reference tests associated with the thyroid panel were not available. Rather, we first estimated the cutoff values for anti-thyroglobulin antibody (TgAb), and anti-thyroid peroxidase antibody (TPOAb) from the probability paper plot drawn with x-axis in logarithmic scale, as an intersection of the central linear part with the horizontal line at 97.5 percentile as shown in [Fig 3](#pone.0235234.g003){ref-type="fig"}.

![Determination of cutoff values for TgAb and TPOAb based on the probability paper plot.\
Cutoff values for thyroglobulin antibody (TgAb), and thyroid peroxidase antibody (TPOAb) were empirically determined by use of the probability paper plot. Y-axis represents cumulative frequencies of RV distribution, while x-axis was drawn in logarithmic scale. We assumed that both antibodies are specific to autoimmune thyroiditis (AIT), and thus extreme values in the tail constitutes a group of values from AIT cases. Therefore, we determined the cutoff value as an intersection of central linear part with the horizontal line at 97.5%.](pone.0235234.g003){#pone.0235234.g003}

For judging the need for adopting LAVE, we computed BR~LL~ and BR~UL~ by setting LLs and ULs of RIs with/without LAVE: i.e., SD~RI~ in the denominator was set to the RI by the LAVE procedure. The 90% confidence intervals (CIs) of LL and UL were derived by the bootstrap method with resampling of the final set of RVs and repeated computations of LL and UL for 50 iterations. Accordingly, final RIs were determined as the averages of LL and UL thus derived.

Results {#sec013}
=======

Profile of the subjects {#sec014}
-----------------------

Out of 596 volunteers, 533 met the inclusion criteria: 260 (48.8%) males and 273 (51.2%) females. The main reason for exclusion was hypertension as shown in [Fig 4](#pone.0235234.g004){ref-type="fig"}.

![Study flowchart.\
BMI: body mass index, CBC: complete blood count, DM: diabetes mellitus, HIV: Human Immunodeficiency Virus, HTN: hypertension. \*On antibiotics, blood donation in past 3 months, on treatment for hypothyroidism, \> 65 years, \> 65 years and hypertensive, rheumatic heart disease, prostate cancer.](pone.0235234.g004){#pone.0235234.g004}

The median age was 39 years with a range of 18--65 years. The participant characteristics are summarized in [Table 2](#pone.0235234.t002){ref-type="table"}.

10.1371/journal.pone.0235234.t002

###### Descriptive characteristics of participants.
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                        Male (n = 260)   Female (n = 273)   Total (n = 533)                              
  --------------------- ---------------- ------------------ ----------------- ------------ ------------- ------------
  Age (years)           39 (18)          20--65             39 (21)           18--64       39 (20)       18--65
  Height (cms)          172 (8)          156--191           160 (9)           143--191     167 (13)      143--191
  Weight (kg)           74 (19)          46--116            68 (16)           38--109      70 (18)       38--116
  BMI (kg/m^2^)         24.9 (5.6)       16.3--34.9         26.1 (6.3)        17.1--38.1   25.5 (5.9)    16.3--38.1
  BSA (m^2^)            1.88 (0.24)      1.44--2.36         1.72 (0.20)       1.27--2.24   1.78 (0.22)   1.27--2.36
  AC (cm)               91 (15)          65--124            86 (16)           64--115      89 (17)       64--124
  BP Systolic (mmHg)    127 (18)         84--179            128 (18)          118 (20)     124 (21)      77--194
  BP Diastolic (mmHg)   81 (12)          56--101            79 (14)           57--112      80 (14)       56--112

AC: abdominal circumference; BMI: body mass index; BSA: body surface area; IQR: interquartile range

Sources of variation {#sec015}
--------------------

Sex, age and BMI as sources of variation were explored with SDR≥0.4 regarded as being significant as shown in [Table 3](#pone.0235234.t003){ref-type="table"}.

10.1371/journal.pone.0235234.t003

###### Standard deviation ratios for between sex and age.
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           SDRsex     SDRage                SDRsex     SDRage                                
  -------- ---------- ---------- ---------- ---------- -------- ---------- ---------- ------ ----------
  TP       0.00       0.36       0.38       0.35       ALT      **0.56**   **0.42**   0.31   **0.52**
  Alb      **0.50**   **0.54**   **0.56**   **0.53**   AST      **0.48**   0.26       0.09   0.34
  Glb      0.32       0.00       0.00       0.00       ALP      0.00       **0.47**   0.16   **0.66**
  Urea     0.30       0.32       0.21       **0.42**   AMY      0.05       0.00       0.00   0.00
  eGFR     0.00       0.32       0.34       0.29       LDH      0.00       0.22       0.00   0.31
  UA       **0.89**   0.38       **0.41**   0.33       CK       **0.50**   0.08       0.02   0.12
  Cre      **1.19**   0.24       0.30       0.14       GGT      **0.51**   0.28       0.35   0.14
  TBil     **0.48**   0.27       0.21       0.32       Iron     0.39       0.09       0.10   0.08
  Na       0.00       0.38       0.14       **0.47**   Ferr     **0.78**   0.26       0.22   **0.45**
  K        0.00       0.23       0.22       0.25       TF       **0.43**   0.18       0.18   0.18
  Cl       **0.44**   0.30       0.38       0.18       TFSat    **0.50**   0.00       0.00   0.00
  Ca       0.16       0.29       0.31       0.26       CRP      0.10       0.31       0.37   0.25
  IP       0.21       0.20       0.22       0.17       IgA      0.00       0.24       0.15   0.31
  Mg       0.00       **0.46**   0.38       **0.52**   IgG      0.10       0.12       0.17   0.07
  Glu      0.00       **0.41**   **0.44**   0.39       IgM      **0.48**   0.12       0.15   0.08
  TC       0.00       **0.41**   **0.41**   **0.42**   FT3      0.12       0.04       0.00   0.09
  TG       0.22       **0.58**   **0.56**   **0.60**   FT4      0.00       0.36       0.35   0.37
  HDL-C    0.33       0.00       0.00       0.00       TSH      0.00       0.00       0.00   0.03
  HDLrat   0.33       0.38       0.39       0.37       TgAb     0.00       0.28       0.27   0.28
  nonHDL   0.00       **0.45**   **0.44**   **0.46**   TPOAb    0.09       0.04       0.06   0.03
  LDL-C    0.00       **0.42**   0.40       **0.43**   Trop I   0.00       0.08       0.00   0.09
  Lip      0.07       0.16       0.17       0.15       PSA                            0.39   

SDR≥0.4 shown in bold; SDR≥0.5 orange background

Between-sex differences exceeded that level in Alb, UA, Cre, TBil, Cl, ALT, AST, CK, GGT, Ferr, Tf, TfSat, and IgM. Similarly, between-age subgroup differences were significant for Alb, Cl, Glu, and TG in males, and for Alb, urea, Na, Mg, Glu, TC, TG, HDLrat, LDL-C, ALT, ALP, and Ferr in females. BMI was an independent source of variation for UA, Glu, TC, HDLrat, nonHDL-C, LDL-C, ALT, AST, LDH, and GGT in males, and for CRP only in females. Graphical representations of reference value distribution sub-grouped by sex and age are shown for 12 representative analytes in [Fig 5](#pone.0235234.g005){ref-type="fig"} and for all analytes in [S1 Fig](#pone.0235234.s001){ref-type="supplementary-material"}.

![Sex and age-related changes for 12 analytes.\
The distributions of reference values are shown based on age and sex stratification for 12 analytes. The SDRsex and SDRage for each sex are shown at the top of each analyte chart. No secondary exclusion was performed in plotting the data. The box in each scattergram represents central 50% range and the vertical bar in the middle represents a median point.](pone.0235234.g005){#pone.0235234.g005}

Reference intervals {#sec016}
-------------------

Generally, the parametric method resulted in similar or lower RI ULs, and narrower 90% CIs for the LL and UL of the RIs compared to the non-parametric method as shown in [S2 Fig](#pone.0235234.s002){ref-type="supplementary-material"}. Besides, the accuracy of Gaussian transformation by the parametric method was confirmed as shown in [S3 Fig](#pone.0235234.s003){ref-type="supplementary-material"}. Therefore, we adopted the RIs derived by the parametric method exclusively. In addition, we could not calculate a RI for Trop I because 94.7% of RVs were below detection limit. For TgAb and TPOAb, we determined cutoff values by use of the probability paper plot as 2.5 IU/ml and 5.0 IU/mL respectively as shown in [Fig 3](#pone.0235234.g003){ref-type="fig"}. We regarded individuals who had antibody values exceeding either of the cutoffs (7.7% of males and 13.6% of females) as possible autoimmune thyroiditis (AIT), and excluded them when calculating RIs for thyroid function tests.

The LAVE method resulted in significant differences in LL or UL (BR~UL~ or BR~LL~ \> 0.375) for some analytes as shown in [S1 Table](#pone.0235234.s005){ref-type="supplementary-material"}. For example, UL lowered for AST, ALT, CRP; LL raised for Fe.

Based on the decision flow chart shown in [Fig 2](#pone.0235234.g002){ref-type="fig"}, RIs for TP, Alb, Glb, Na, K, Cl, Ca, IP, Glu, TG, HDL-C, nonHDL, Lip, AMY, LDH, CRP, Fe, IgG and IgA were not partitioned by sex as shown in [Table 4](#pone.0235234.t004){ref-type="table"}. For age partitions, although the mean age of menopause for females is about 50 years, we chose 45 years as the borderline because there were limited number of subjects above the age of 50.

10.1371/journal.pone.0235234.t004

###### Proposed reference intervals.
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                           M + F   M      F                                         
  -------- -------- ------ ------- ------ ------- ----- ------ ------ ------ ------ ------
  TP       g/L      All    526     67     83                                        
  Alb      g/L      \~45   349     39     50                                        
  45\~     150      39     47                                                       
  Glb      g/L      All    524     24     38                                        
  Urea     mmol/L   All                           258   2.4    6.6                  
  \~45                                                  145    1.8    5.2           
  45\~                                                  83     1.8    6.4           
  UA       mmol/L   All                           259   238    532    272    178    417
  Cre      μmol/L   All                           260   58     109    271    45     86
  TBil     μmol/L   All                           257   6      43     271    5      27
  Na       mmol/L   All    531     134    142                                       
  K        mmol/L   All    531     3.4    4.8                                       
  Cl       mmol/L   All    501     100    110                                       
  Ca       mmol/L   All    531     2.19   2.57                                      
  IP       mmol/L   All    533     0.78   1.42                                      
  Mg       mmol/L   All                           260   0.73   0.98                 
  \~45                                                  174    0.71   0.93          
  45\~                                                  99     0.76   1.01          
  Glu      mmol/L   \~45   345     3.9    5.8                                       
  45\~     172      4.4    7.3                                                      
  TC       mmol/L   All                           260   3.1    6.9                  
  \~45                                                  174    3.1    6.2           
  45\~                                                  99     3.2    7.1           
  TG       mmol/L   \~45   289     0.47   2.60                                      
  45\~     154      0.55   3.70                                                     
  HDL-C    mmol/L   All    530     0.7    1.7                                       
  HDLrat            All                           259   2.6    7.6                  
  \~45                                                  174    2.4    5.9           
  45\~                                                  98     2.7    6.7           
  nonHDL   mmol/L   All    532     2.0    5.6                                       
  LDL-C    mmol/L   All                           260   1.6    4.8                  
  \~45                                                  174    1.5    4.2           
  45\~                                                  99     1.7    4.9           
  Lip      U/L      All    527     9      68                                        
  ALT      IU/L     All                           202   10     55     229    7      30
  AST      IU/L     All                           206   17     40     227    15     29
  ALP      IU/L     All                           260   53     153                  
  \~45                                                  172    47     130           
  45\~                                                  99     55     174           
  AMY      IU/L     All    530     47     164                                       
  LDH      IU/L     All    530     138    257                                       
  CK       IU/L     All                           259   72     460    268    53     260
  GGT      IU/L     All                           199   13     90     269    10     50
  CRP      mg/L     All    425     0.21   14.67                                     
  Fe       μmol/L   All    412     8.8    28.9                                      
  Ferr     μg/L     All                           253   10     475                  
  \~45                                                  173    2      150           
  45\~                                                  99     0      222           
  Tf       g/L      All                           254   1.9    3.2    206    2.0    3.5
  TfSat    \%       All                           208   15     49     211    10     44
  IgG      g/L      All    525     11.1   20.0                                      
  IgA      g/L      All    526     1.05   4.63                                      
  IgM      g/L      All                           254   0.38   2.29   272    0.51   2.77
  FT3      pmol/L   All    467     3.9    6.3                                       
  FT4      pmol/L   All    468     7.8    14.1                                      
  TSH      mIU/L    All    461     0.61   4.86                                      
  PSA      μg/L     All                           243   0.29   2.92                 

A comparison of our RIs with those recommended by Beckman coulter and those derived from IFCC studies conducted in India, Saudi Arabia and Turkey found much higher RIs for TBil as shown in [Table 5](#pone.0235234.t005){ref-type="table"}. A similar comparison that also includes studies carried out in other African countries is shown in [S2 Table](#pone.0235234.s006){ref-type="supplementary-material"}.

10.1371/journal.pone.0235234.t005

###### Comparison of reference intervals.

![](pone.0235234.t005){#pone.0235234.t005g}

                    PRESENT STUDY KENYA   BECKMAN AU \[[@pone.0235234.ref022]\]   SAUDI ARABIA \[[@pone.0235234.ref012]\]   TURKEY \[[@pone.0235234.ref013]\]   INDIA \[[@pone.0235234.ref015]\]                                                                                                                                                                                                                          
  -------- -------- --------------------- --------------------------------------- ----------------------------------------- ----------------------------------- ---------------------------------- ------ ------ ---- ------ ------- ------- ------- ------- ------ -------- ------ ------ ------ ------ -------- ------ -------- ------ ------ ------ ------ -------- ------ -------- ------ ------ ------ ------ ------ ------
  TP       g/L      18--65                67                                      83                                                                                                                             NA   66     83                                     18--65   66     83                                   20--79   66     82                                   18--65   68     86                          
  Alb      g/L      18--65                                                                                                                                                                                       NA   35     52                                     18--65   39     50                                   20--79   41     49                                   18--65                               36     47
  18--44                                  40                                      51                                        38                                  49                                                                                                                                                                                                                                                        
  45--65                                  40                                      47                                        38                                  46                                                                                                                                                                                                                                                        
  Urea     mmol/L   18--65                                                                                                  2.4                                 6.6                                              NA   2.8    7.2                                    18--65                 2.8    7.3    2.1      6.4                                                         18--65                 2.2    6.0           
  18--44                                                                                                                    1.8                                 5.3                                                                                                                                      20--49                   2.95   7.20   2.21   6.12   18--45                                 1.9    5.1           
  45--65                                                                                                                    1.9                                 6.2                                                                                                                                      50--79                                 2.85   7.96   46--65                                 2.4    6.7           
  UA       μmol/L   18--65                                                                                                  243                                 507                                178    417    NA                  208.3   428.4   154.7   357    18--65                 223    444    148      321    20--79                 226    458    166      345    18--65                 248    509    159    404
  Cre      μmol/L   18--65                                                                                                  58                                  109                                45     86     NA                  59      104     45      84     18--65                 66     111    50       74     20--79                 59     92     50       71     18--65                 58     95     35     74
  TBil     μmol/L   18--65                                                                                                  6                                   43                                 5      27     NA   5      21                                     18--65                 3.6    22.4   2.2      15.5   20--79                 3.8    24.1   2.7      15.9   18--65                 6.2    23.7   4      17.3
  Na       mmol/L   18--65                134                                     142                                                                                                                            NA   136    146                                    18--65   135    144                                  20--79   137    144                                  18--65   135    146                         
  K        mmol/L   18--65                3.4                                     4.8                                                                                                                            NA   3.5    5.1                                    18--65   3.7    4.9                                  20--79   3.7    4.9                                  18--65   3.8    5                           
  Cl       mmol/L   18--65                100                                     110                                                                                                                            NA   101    109                                    18--65   101    111                                  20--79   99     107                                  18--65   102    113                         
  Ca       mmol/L   18--65                2.19                                    2.57                                                                                                                           NA   2.2    2.65                                   18--65   2.11   2.56                                 20--79   2.15   2.47                                 18--65   2.1    2.44                        
  IP       mmol/L   18--65                0.78                                    1.42                                                                                                                           NA   0.81   1.45                                   18--65   0.81   1.44                                 20--79   0.8    1.4                                  18--65   0.8    1.43                        
  Mg       mmol/L   18--65                                                                                                  0.73                                0.98                                             NA                  0.73    1.06    0.77    1.03   18--65   0.71   0.96                                 20--79   0.77   1.06                                 18--65   0.77   1.07                        
  18--44                                                                                                                    0.71                                0.93                                                                                                                                                                                                                                                      
  45--65                                                                                                                    0.76                                1.01                                                                                                                                                                                                                                                      
  Glu      mmol/L   18--65                                                                                                                                                                                       NA   4.1    5.9                                    18--65   4      5.9                                  20--79   3.96   5.88                                 18--65                                      
  18--44   3.9      5.8                                                                                                                                                                                                                                                                                                                                       18--45   4.1    5.5                                         
  45--65   4.4      7.3                                                                                                                                                                                                                                                                                                                                       46--65   4.3    6.0                                         
  TC       mmol/L   18--65                                                                                                                                                                                       NA          5.2                                    18--65   3.5    6.36                                                                                      18--65                               2.9    6.6
  18--45   3.10     6.10                                                                                                                                                                                                                                                                                 20--49   3.22   6.45     3.20   6.42   3.20   6.38   18--45                   3.1    6.2                         
  46--65   3.20     7.20                                                                                                                                                                                                                                                                                 50--79                                 3.93   7.92   46--65                   2.5    6.7                         
  TG       mmol/L   18--65                                                                                                                                                                                       NA          1.7                                    18--65                 0.5    3.58   0.39     1.6                                                         18--65                 0.6    2.7    0.5    2.1
  18--45                                  0.50                                    2.88                                      0.45                                2.03                                                                                                                                     20--49                   0.53   3.39   0.46   2.52   18--45                                                      
  46--65                                  0.53                                    3.87                                      0.55                                3.24                                                                                                                                     50--79                                 0.64   3.55   46--65                                                      
  HDL-C    mmol/L   18--65                0.70                                    1.70                                                                                                                           NA   1.03   1.55                                   18--65                 0.74   1.76   0.98     2.19                          0.85   1.52   0.95     1.56   18--65                 0.7    1.5    0.8    1.8
  LDL-C    mmol/L   18--65                                                                                                  1.60                                4.80                                             NA          2.60                                   18--65   1.8    4.34                                                                                      18--65   1.7    4.4                         
  18--44                                                                                                                    1.50                                4.20                                                                                                                                     20--49   1.47   3.92     1.60   4.01   1.32   3.92   18--45                                                      
  45--65                                                                                                                    1.70                                4.90                                                                                                                                     50--79                                 1.78   4.91   46--65                                                      
  Lip      U/L      18--65                                                                                                  8                                   75                                 10     63     NA          67                                                                                                                                               18--65                                      
  ALT      IU/L     18--65                                                                                                  10                                  55                                 7      30     NA                          50              35     18--65                 7      39     5        18                            9      57     7        28     18--65                 15     74     10     37
  AST      IU/L     18--65                                                                                                  17                                  40                                 15     29     NA                          50              35     18--65                 11     28     10       24                            13     30     11       25     18--65                 20     53     17     39
  ALP      IU/L     18--65                                                                                                  53                                  153                                              NA   30     120                                             39     114                                                                                       18--65                 41     111           
  18--44                                                                                                                    47                                  130                                                                                                                                      20--49   38     112      43     116    34     97     18--45                                 35     100           
  45--65                                                                                                                    55                                  174                                                                                                                                      50--79                                 47     133    46--65                                 43     117           
  AMY      IU/L     18--65                47                                      164                                                                                                                            NA   22     80                                     18--65   31     117                                           34     119                                  18--65   36     135                         
  LDH      IU/L     18--65                138                                     257                                                                                                                            NA                          248             247    18--65   10     238                                           126    220                                  18--65   104    206                         
  CK       IU/L     18--65                                                                                                  72                                  460                                53     260    NA                          171             145    18--65                 54     266    27       138                           48     227    34       131    18--65                 48     304    36     184
  GGT      IU/L     18--65                                                                                                  13                                  90                                 10     47     NA                          55              38     18--65                 11     65     7        21                            11     69     7        33     18--65                 14     62     11     40
  Fe       μmol/L   18--65                8.8                                     28.9                                                                                                                           NA                  12.5    32.2    10.7    32.2   18--65                 7.9    29.6   3.7      26                            5.9    31.6   3.5      27.8   18--65                 7      33     4      26
  Ferr     μg/L     18--65                                                                                                  20                                  457                                              NA                  20      250     10      120                                                         18--79                               4.7      136    18--65                                      
  18--44                                                                                                                    5                                   150                                                                                                                                      18--44                   13     276    4.3    91                                                                 
  45--65                                                                                                                    12                                  232                                                                                                                                      45--79                                 5.9    175                                                                
  Tf       g/L      18--65                                                                                                  1.9                                 3.2                                2.0    3.5    NA   2      3.6                                    18--65                 2      3.2    2.1      3.9    18--79   1.8    3.3    1.8    3.3    1.9      3.5    18--65   2.2    4                           
  TfSat    \%       18--65                13                                      47                                                                                                                                                                                                                                                                                          18--65                                      
  CRP      mg/L     18--65                0.21                                    14.7                                                                                                                           NA          1                                      18--65   0.2    11.8                                                                                      18--65                 0.33   7.34   0.35   11.9
  IgA      g/L      18--65                1.05                                    4.63                                                                                                                           NA   0.7    4                                                                                                                                                18--65   0.94   4.35                        
  IgG      g/L      18--65                11.1                                    20.0                                                                                                                           NA   7      16                                                                                                                                               18--65   9.1    20.4                        
  IgM      g/L      18--65                                                                                                  0.38                                2.29                               0.51   2.77   NA   0.4    2.3                                                                                                                                              18--65                 0.4    2.54   0.51   3.1
  FT3      pmol/L   18--65                3.9                                     6.3                                                                                                                            NA   3.8    6                                                                                                                                                18--65                                      
  FT4      pmol/L   18--65                7.8                                     14.1                                                                                                                           NA   7.86   14.41                                                                                                                                            18--65                                      
  TSH      mIU/L    18--65                0.61                                    4.86                                                                                                                           NA   0.38   5.33                                                                                                                                             18--65                                      
  PSA      μg/L     18--65                                                                                                  0.25                                2.95                                                                                                                                                                                                          18--65                                      

Standardization of the RIs {#sec017}
--------------------------

Since this study utilized a serum panel provided by C-RIDL which comprised 50 samples with values assigned to 25 chemistry analytes, we confirmed the standardized status of the assays as shown in [S4 Fig](#pone.0235234.s004){ref-type="supplementary-material"}. For the method comparison, major-axis regression was used to express the structural relationship between our test results and the panel assigned values by calculating BR~LL~ or BR~UL~ as a difference of LL or UL before and after the recalibration using the regression coefficients. As a result, we found it necessary to recalibrate our RIs for HDL-C and LDH. For Na, we could not get a good linear relationship because of poor precision of the assay with the narrow reference interval.

Discussion {#sec018}
==========

There have been controversies over the statistical methods used in deriving RIs. They include: selection between parametric and nonparametric methods, how and when to exclude RVs secondarily, and when to partition RVs into subgroups by sex and age. In this study we sought optimal options for each. We found the nonparametric method of limited use with its wider 90% CI for RIs and frequent bias in UL ([S1 Fig](#pone.0235234.s001){ref-type="supplementary-material"}), while the parametric method was found to be more reliable after successful Gaussian transformation ([S3 Fig](#pone.0235234.s003){ref-type="supplementary-material"}). For secondary exclusion, we found LAVE procedure effective for reducing the influence of over nutrition for those analytes with high association with BMI such as TG, ALT, AST, and CRP. It was also effective in reducing the influence of latent inflammation and anemia on Fe, Tf and TfSat.

In order to decide the need for partitioning RVs into subgroups by sex or age, we primarily used SDR, but it tended to provide an inflated value when the width of the RI was narrow. Another problem of SDR is that it reflects between-subgroup difference at the central part which may not reflect between-subgroup bias at the LL or UL, hence the use of BR~LL~ or BR~UL~. Furthermore, we found it necessary to confirm the appropriateness of BR~LL~ or BR~UL~ by quantitating the actual difference at LL or UL by use of the reporting unit (RU). We chose to adopt partitioned RIs only when the difference at LL or UL was ≥3RU. We believe this three-way consideration ensured optimal judgement in partitioning RIs by sex and age as shown in [S1 Table](#pone.0235234.s005){ref-type="supplementary-material"}.

RIs can vary appreciably across different populations as demonstrated in the interim report of the global study analyzing RVs of 12 countries \[[@pone.0235234.ref004]\]. They identified ethnic differences in many analytes such as Alb, urea, TBil, HDL-C, CRP, IgG, C3, and PTH. In reference to the RV profiles, we noted certain unique features of Kenyan RIs. For instance, our urea RIs are lower than those from Turkey and Saudi Arabia. Although most of our RIs for liver function tests were similar to published reports from Saudi Arabia and Turkey \[[@pone.0235234.ref012],[@pone.0235234.ref013]\], our TBil RI of 6--43 μmol/L for males and 5--27 μmol/L for females is almost double what has been reported in published studies from outside the African continent as shown in [S2 Table](#pone.0235234.s006){ref-type="supplementary-material"} \[[@pone.0235234.ref002],[@pone.0235234.ref012]--[@pone.0235234.ref015]\]. We hypothesize that Gilbert's syndrome, the commonest genetic cause of asymptomatic unconjugated hyperbilirubinaemia, could be quite prevalent in our population. Genetic studies would thus be useful in elucidating the cause of hyperbilirubinaemia observed in our study.

Our electrolytes didn't differ much from other published IFCC studies except that Mg levels increased with age in females. It has been documented that reduced levels of oestrogen are associated with increased Mg levels in post-menopausal women as well as in the follicular phase of the menstrual cycle in women of reproductive age \[[@pone.0235234.ref016],[@pone.0235234.ref017]\].

Our TC and TG RIs were higher than those reported by Kibaya *et al* who carried out a similar study in a rural Kenyan population \[[@pone.0235234.ref018]\]. Our study population was primarily composed of urban dwellers of whom 25.6% had metabolic syndrome \[[@pone.0235234.ref019]\]. According to the third report of the National Cholesterol Education Program (NCEP), the desirable LDL-C level for low risk adults is \<4.1 mmol/L \[[@pone.0235234.ref020]\]. Our UL for LDL-C in males (4.8 mmol/L) and in females (4.2 and 4.9 mmol/L) are higher than the NCEP targets. However, the NCEP clinical decision limits (CDLs) are used for diagnosis of hyperlipidaemia and serve as treatment targets for reducing cardiovascular risk. Aside from the risk of over-nutrition, the RI ULs for TC and LDL-C are important in diagnosing cholestatic conditions and hypothyroidism. These are relatively short-term conditions unrelated to occurrence of atherosclerosis hence the RIs are more relevant than CDLs in their diagnosis. On the other hand, determination of LLs for TC or LDL-C RIs are essential for diagnosing malnutrition or thyrotoxicosis. Therefore, we are not replacing the derived RIs with those CDLs, rather providing CDLs in the footnote of test result report sheet.

We obtained fasting plasma glucose (FPG) RIs of 3.9−5.8 and 4.4−7.3 mmol/L for those aged \<45 and ≥45 years respectively. The former RI is comparable to what was obtained in Turkey (3.96−5.88 mmol/L) and Saudi Arabia (4.0−5.9 mmol/L) \[[@pone.0235234.ref012],[@pone.0235234.ref013]\]. The American Diabetes Association (ADA) uses FPG ≥ 5.6 and 7.0 mmol/L to define pre-diabetes and diabetes respectively. Based on the ADA criteria, a total of 63 out of 528 participants would have been classified as having elevated values compared to 20 if the ULs of the derived RIs were used.

Our RIs for immunoglobulins are higher than those derived in the US but very similar to those derived in India \[[@pone.0235234.ref002],[@pone.0235234.ref015]\]. Karita *et al* also found high levels of IgG in several SSA countries \[[@pone.0235234.ref021]\]. We hypothesize that this may be due to inflammation caused by increased exposure to either infectious disease agents or environmental allergens. The increased inflammation is further evidenced by the very high RI UL for CRP of 14.7 mg/L compared to 1 mg/L recommended by Beckman Coulter \[[@pone.0235234.ref022]\]. Ichihara *et al* in a similar study carried out in Asia found that the closer the country or region was to the equator, the higher the serum concentrations of positive inflammatory markers (IgG, C3, CRP) a phenomenon they ascribed to increased exposure to infectious agents \[[@pone.0235234.ref023]\]. Similar to the IFCC study in India, IgM was significantly higher in female participants requiring the determination of sex specific RIs \[[@pone.0235234.ref015]\]. We hypothesize that this could be linked to the role that estrogen plays in enhancing humoral immunity \[[@pone.0235234.ref024]\].

Ichihara *et al* has demonstrated that BMI is a major source of variation in RVs for many analytes and that the magnitude of this association varies across different populations \[[@pone.0235234.ref025]\]. For example, a similar change in BMI resulted in a greater decline in HDL cholesterol amongst the Japanese (r = −0.39) compared to people from Pakistan (r = −0.05). On the other hand, an increase in BMI was associated with a greater increase in ALT values (r = 0.48) amongst non-black South Africans compared to black South Africans (r = 0.02) \[[@pone.0235234.ref025]\]. BMI was a source of variation for several analytes in males especially those known to be associated with the presence of metabolic syndrome such as Glu, LDL-C, and ALT. We did not partition our RIs by BMI because the influence of BMI was suppressed by use of the LAVE method.

For iron markers, we also applied LAVE to reduce the influence of latent anemia. Although it was very effective in raising their LLs, the female LL for ferritin was still lower than the WHO cutoff value of \<15 μg/L for iron deficiency \[[@pone.0235234.ref026]\].

The strengths of our study include the deliberate recruitment of healthy individuals using a harmonized protocol to ensure pre-analytical confounders were minimized, centralized analysis of samples in an accredited laboratory with excellent internal quality control, standardization of the RIs by use of a value-assigned panel of sera and use of the LAVE procedure to reduce the influence of sub-clinical disease on the derived RIs.

The weaknesses include failure to perform infectious serology to rule out chronic infections such as HIV, HBV or HCV, and over representation of an urban population hence limiting the generalizability of our findings to a rural population.

Conclusion {#sec019}
==========

According to the harmonized IFCC-C-RIDL protocol, we established RIs for 40 major chemistry and immunoassay tests from well-defined healthy Kenyan volunteers by use of the up-to-date statistical methods for the first time in Africa. The LAVE method was effective in reducing the influence on RIs of latent anemia and metabolic disorders. Based on SD ratio and bias ratios, we developed a flow chart to judge the need for partitioning RVs by sex and age subgroups, which we believe is helpful for the future RI study. RIs for chemistry analytes were standardized by use of a value assigned serum panel, and thus could be shared across sub-Saharan African laboratories with similar ethnic and life-style profile. As a whole, Kenyan RIs were comparable to those of other countries participating in the global study with a few exceptions such as higher ULs for TBil and CRP.

Supporting information {#sec020}
======================

###### Sex and age-related changes.

The distributions of reference values are shown based on age and sex stratification for all analytes. The SDRsex and SDRage for each sex are shown at the top of each analyte chart. No secondary exclusion was performed in plotting the data. The box in each scattergram represents central 50% range and the vertical bar in the middle represents a median point.

(PDF)

###### 

Click here for additional data file.

###### Bar-chart comparison of reference interval calculation methods.

The RIs of all analytes were derived in four ways by parametric (P) or nonparametric (NP) method with/without the LAVE procedure, separately in males+Females (MF), males, and females. Each horizontal bar represents the range of the RI, and the vertical line in the center corresponds to the mid-point. The shades on both ends of the bar represent 90%CI for the limits of the RI predicted by the bootstrap method.

(PDF)

###### 

Click here for additional data file.

###### Results of Gaussian transformation by the parametric method.

The accuracy of Gaussian transformation by Box-Cox formula can be assessed from theoretical Gaussian curves in two histograms shown on left top (before and after the transformation) of each panel. Accuracy can be also seen from the linearity in probability paper plot on the right. The limits of the RI by nonparametric method corresponds to the points where red zigzag line intersect with horizontal 2.5 and 97.5% red lines of cumulative frequencies.

(PDF)

###### 

Click here for additional data file.

###### Panel test results for assessment of standardized status of assays.

The panel of sera from 50 healthy volunteers, each of which were value assigned for 40 chemistry analytes were measured. Our measured values were plotted on Y-axis and assigned values on X-axis. Major axis linear regression was used as a structural relationship for the method comparison. The Y = X line is shown as a diagonal broken line.

(PDF)

###### 

Click here for additional data file.

###### Reference intervals and determination of method, sex and age bias.

(PDF)

###### 

Click here for additional data file.

###### Comparison of reference intervals.

(PDF)

###### 

Click here for additional data file.
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